Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.12)
# 1,524
Out of 4,413 analysts
49
Total ratings
44.9%
Success rate
-8.17%
Average return
Main Sectors:
Top Industries:
15 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASND Ascendis Pharma | Reiterates: Overweight | $173 | $141.01 | +22.69% | 8 | Apr 18, 2024 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | n/a | $16.94 | - | 2 | Apr 12, 2024 | |
| VINC Vincerx Pharma | Reiterates: Overweight | n/a | $0.89 | - | 5 | Apr 9, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Overweight | n/a | $1.61 | - | 3 | Apr 1, 2024 | |
| AFMD Affimed | Reiterates: Overweight | n/a | $5.35 | - | 5 | Apr 1, 2024 | |
| SLS SELLAS Life Sciences Group | Reiterates: Overweight | $3 | $1.28 | +134.38% | 3 | Nov 22, 2023 | |
| RCUS Arcus Biosciences | Maintains: Overweight | $46 → $36 | $15.50 | +132.26% | 1 | Nov 8, 2023 | |
| BCYC Bicycle Therapeutics | Reiterates: Overweight | $65 | $24.20 | +168.60% | 4 | Nov 8, 2023 | |
| PRTG Portage Biotech | Reiterates: Overweight | $11 | $0.23 | +4,682.61% | 3 | Sep 7, 2023 | |
| ONCT Oncternal Therapeutics | Reiterates: Neutral | $26 | $8.25 | +215.15% | 3 | Sep 7, 2023 | |
| KURA Kura Oncology | Reiterates: Overweight | $30 | $20.28 | +47.93% | 4 | Sep 7, 2023 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $5 | $4.09 | +22.25% | 3 | Sep 7, 2023 | |
| ARVN Arvinas | Reiterates: Overweight | $70 | $32.48 | +115.52% | 2 | Sep 7, 2023 | |
| APTO Aptose Biosciences | Reiterates: Overweight | $38 | $1.21 | +3,040.50% | 2 | Sep 7, 2023 | |
| NKTX Nkarta | Maintains: Overweight | $60 → $38 | $7.49 | +407.34% | 1 | Aug 12, 2022 |
Ascendis Pharma
Apr 18, 2024
Reiterates: Overweight
Price Target: $173
Current: $141.01
Upside: +22.69%
ALX Oncology Holdings
Apr 12, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.94
Upside: -
Vincerx Pharma
Apr 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.89
Upside: -
Corvus Pharmaceuticals
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.61
Upside: -
Affimed
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.35
Upside: -
SELLAS Life Sciences Group
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.28
Upside: +134.38%
Arcus Biosciences
Nov 8, 2023
Maintains: Overweight
Price Target: $46 → $36
Current: $15.50
Upside: +132.26%
Bicycle Therapeutics
Nov 8, 2023
Reiterates: Overweight
Price Target: $65
Current: $24.20
Upside: +168.60%
Portage Biotech
Sep 7, 2023
Reiterates: Overweight
Price Target: $11
Current: $0.23
Upside: +4,682.61%
Oncternal Therapeutics
Sep 7, 2023
Reiterates: Neutral
Price Target: $26
Current: $8.25
Upside: +215.15%
Kura Oncology
Sep 7, 2023
Reiterates: Overweight
Price Target: $30
Current: $20.28
Upside: +47.93%
Fate Therapeutics
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $4.09
Upside: +22.25%
Arvinas
Sep 7, 2023
Reiterates: Overweight
Price Target: $70
Current: $32.48
Upside: +115.52%
Aptose Biosciences
Sep 7, 2023
Reiterates: Overweight
Price Target: $38
Current: $1.21
Upside: +3,040.50%
Nkarta
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $7.49
Upside: +407.34%